Skip to content

Publications

Explore the data that validate our scientific approach to mobilizing the full power of the immune system to defeat a wide range of cancers.

Publications Posters

Featured Presentation

San Antonio Breast Cancer Symposium

December 2024

A Phase 1b/2 Study of Evorpacept plus Zanidatamab in Patients with HER2-Positive and HER2-Low Metastatic Breast Cancer

View Poster

Filter by Indication

No presentations found for this year and indication.

  • San Antonio Breast Cancer Symposium
    December 2024

    A Phase 1b/2 Study of Evorpacept plus Zanidatamab in Patients with HER2-Positive and HER2-Low Metastatic Breast Cancer

    View Poster
  • American Society of Clinical Oncology Annual Meeting
    June 2024

    A Phase 1a Study of Evorpacept plus Enfortumab Vedotin in Patients with Locally Advanced or Metastatic Urothelial Carcinoma

    View Poster
  • American Society of Clinical Oncology Annual Meeting
    June 2024

    A Phase 2 Study of Evorpacept, Cetuximab, and Pembrolizumab in Patients with Refractory Microsatellite Stable Metastatic Colorectal Cancer

    View Poster
  • American Association for Cancer Research Annual Meeting
    April 2024

    A Phase 1 Investigator-Initiated Trial of Evorpacept (ALX148), Lenalidomide and Rituximab for Patients with Relapsed or Refractory B-Cell non-Hodgkin lymphoma

    View Presentation
  • American Association for Cancer Research Annual Meeting
    April 2024

    A Phase 1 Study of Azacitidine in Combination with Evorpacept for Higher-Risk Myelodysplastic Syndrome (MDS); ASPEN-02

    View Poster

No presentations found for this year and indication.

  • American Society of Hematology Annual Meeting
    December 2022

    Evorpacept, a CD47-Blocking Myeloid Checkpoint Inhibitor, in Combination with Azacitidine and Venetoclax in Patients with Acute Myeloid Leukemia (ASPEN-05): Results from Phase 1a Dose Escalation Part

    View Poster
  • Society for Immunotherapy of Cancer Annual Meeting
    November 2022

    A Phase 2 Study of Evorpacept (ALX148) in Combination with Pembrolizumab and Chemotherapy in Patients with Advanced Head and Neck Squamous Cell Carcinoma (HNSCC); ASPEN-04

    View Poster
  • Society for Immunotherapy of Cancer Annual Meeting
    November 2022

    A Phase 2 Study of Evorpacept (ALX148) in Combination with Pembrolizumab in Patients with Advanced Head and Neck Squamous Cell Carcinoma (HNSCC); ASPEN-03

    View Poster

No presentations found for this year and indication.

  • American Society of Hematology Annual Meeting
    December 2021

    Evorpacept (ALX148), a CD47-Blocking Myeloid Checkpoint Inhibitor, in Combination with Azacitidine: A Phase 1/2 Study in Patients with Myelodysplastic Syndrome (ASPEN-02)

    View Poster
  • Society for Immunotherapy of Cancer Annual Meeting
    November 2021

    A Phase 2 Study of Evorpacept (ALX148) in Combination with Pembrolizumab and Chemotherapy in Patients with Advanced Head and Neck Squamous Cell Carcinoma (HNSCC); ASPEN-04

    View Poster
  • Society for Immunotherapy of Cancer Annual Meeting
    November 2021

    A Phase 2 Study of Evorpacept (ALX148) in Combination with Pembrolizumab in Patients with Advanced Head and Neck Squamous Cell Carcinoma (HNSCC); ASPEN-03

    View Poster
  • Society for Immunotherapy of Cancer Annual Meeting
    November 2021

    ALTA-002, a SIRPα-Directed TLR9 Agonist Antibody Conjugate, Activates Myeloid Cells and Promotes Anti-Tumor Immunity

    View Poster
  • Society for Immunotherapy of Cancer Annual Meeting
    November 2021

    Evorpacept (ALX148), a CD47 Myeloid Checkpoint Inhibitor, in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC) and with Gastric/Gastroesophageal Cancer (GC); ASPEN-01

    View Poster
  • European Society for Medical Oncology – Gastrointestinal Cancers Congress
    January 2021

    ASPEN-01: A Phase 1 Study of ALX148, a CD47 Blocker, in Combination with Trastuzumab, Ramucirumab, and Paclitaxel in Patients with 2nd Line HER2-Positive Advanced Gastric or Gastroesophageal Cancer

    View Poster
  • Frontiers in Cancer Immunotherapy
    January 2021

    CD47 – A Clinically Validated Myeloid Checkpoint

    View Presentation

No presentations found for this year and indication.

  • American Society of Hematology Annual Meeting
    December 2020

    ALX148, a CD47 Blocker, in Combination with Rituximab in Patients with Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma; ASPEN-01

    View Presentation
  • American Society of Hematology Annual Meeting
    December 2020

    ALX148 Enhances the Depth and Durability of Response to Multiple AML Therapies

    View Presentation
  • Society for Immunotherapy of Cancer Annual Meeting
    November 2020

    ALX148, a CD47 Blocker, in Combination with Standard Chemotherapy and Antibody Regimens in Patients with Gastric/Gastroesophageal Junction (GC) Cancer and Head and Neck Squamous Cell Carcinoma (HNSCC); ASPEN-01

    View Poster
  • SIRPα Summit
    November 2020

    ALX148: Designed for Safety to Maximize Efficacy

    View Presentation
  • European Hematology Association Annual Congress
    June 2020

    ALX148, a CD47 Blocker, in Combination with Rituximab in Patients with Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma

    View Poster
  • American Society of Clinical Oncology Annual Meeting
    June 2020

    A Phase 1 Study of ALX148, a CD47 Blocker, in Combination with Standard Anti-Cancer Antibodies and Chemotherapy Regimens in Patients with Advanced Malignancy

    View Poster

No presentations found for this year and indication.

  • American Society of Hematology Annual Meeting
    December 2019

    A Phase 1 Study of ALX148, a CD47 Blocker, in Combination with Rituximab in Patients with Non-Hodgkin Lymphoma

    View Poster
  • Society for Immunotherapy of Cancer Annual Meeting
    November 2019

    Pharmacodynamic Biomarker Characterization of ALX148, a CD47 Blocker, in Combination with Established Anticancer Antibodies in Patients with Advanced Malignancy

    View Poster
  • American Society of Clinical Oncology Annual Meeting
    June 2019

    A Phase 1 Study of ALX148, a CD47 Blocker, in Combination with Established Anticancer Antibodies in Patients with Advanced Malignancy

    View Poster
  • American Association for Cancer Research Annual Meeting
    April 2019

    Antibodies to SIRPα Enhance Innate and Adaptive Immune Responses to Promote Anti-Tumor Activity

    View Poster
  • Keystone Symposia
    February 2019

    Discovery of Monoclonal Antibodies Targeting Myeloid Checkpoint SIRPα to Enhance Anti-Tumor Immunity

    View Poster

No presentations found for this year and indication.

  • Society for Immunotherapy of Cancer Annual Meeting
    November 2018

    A Phase 1 Study of ALX148: CD47 Blockade in Combination with Anti-Cancer Antibodies to Bridge Innate and Adaptive Immune Responses for Advanced Malignancy

    View Poster
  • Society for Immunotherapy of Cancer Annual Meeting
    November 2018

    Pharmacokinetic and Pharmacodynamic Characterization of ALX148, a CD47 Blocker, in Patients with Advanced Malignancy and Non-Hodgkin Lymphoma

    View Poster
  • Society for Immunotherapy of Cancer Annual Meeting
    November 2018

    Oral Presentation: A Phase 1 Study of ALX148: CD47 Blockade in Combination with Anti-Cancer Antibodies to Bridge Innate and Adaptive Immune Responses for Advanced Malignancy

    View Presentation
  • American Society of Clinical Oncology Annual Meeting
    June 2018

    A Phase 1 Study of ALX148, a CD47 Blocker, Alone and in Combination with Established Anti-Cancer Antibodies in Patients with Advanced Malignancy and Non Hodgkin Lymphoma

    View Poster

No presentations found for this year and indication.

  • American Society of Hematology Annual Meeting
    December 2017

    Oral Presentation: ALX148 is a High Affinity SIRPα Fusion Protein that Blocks CD47, Enhances the Activity of Anti-Cancer Antibodies and Checkpoint Inhibitors, and Has a Favorable Safety Profile in Preclinical Models

    View Slides
  • Society for Immunotherapy of Cancer Annual Meeting
    November 2017

    A First-in-Human Study of ALX148: CD47 Blockade to Enhance Innate and Adaptive Immunity for Advanced Solid Tumor Malignancy and Non-Hodgkin Lymphoma

    View Poster

Publications

Evorpacept Alone and in Combination with Pembrolizumab or Trastuzumab in Patients with Advanced Solid Tumors (ASPEN-01): a First-in-Human, Open-Label, Multicentre, Phase 1 Dose-Escalation and Dose-Expansion Study

View Article

Targeting the Myeloid Checkpoint Receptor SIRPα Potentiates Innate and Adaptive Immune Responses to Promote Anti Tumor Activity

View Article

Assessing and Mitigating the Interference of ALX148, a Novel CD47 Blocking Agent, in Pretransfusion Compatibility Testing

View Article

Discovery of High Affinity, Pan-Allelic, and Pan-Mammalian Reactive Antibodies Against the Myeloid Checkpoint Receptor SIRPα

View Article

ALX148 Blocks CD47 and Enhances Innate and Adaptive Antitumor Immunity with a Favorable Safety Profile

View Article

Based on the demonstrated potential of evorpacept, we are swiftly advancing this novel CD47-blocking agent in the clinic to investigate a wide range of cancer indications.

Explore Our Pipeline